Cytokines as emerging targets in the treatment of heart failure

Trends in Cardiovascular Medicine

Volumn 10, Issue 5, 2000, Pages 216-223

  Baumgarten, Georg ^a   Knuefermann, Pascal ^a   Mann, Douglas L ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 6; NEUROHORMONE; TUMOR NECROSIS FACTOR;

CLINICAL TRIAL; DISEASE COURSE; DRUG TARGETING; HEART FAILURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

CYTOKINES; HEART FAILURE, CONGESTIVE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034468570     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1050-1738(00)00063-3     Document Type: Review

References (49)

1. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
2. Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
3. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats
4. Tumor necrosis factor-a and tumor necrosis factor receptors in human heart failure
5. Interleukin-6 correlates with hemodynamic impairment during dobutamine administration in chronic heart failure
6. A phase I trial of tumor necrosis factor receptor (p75) fusion protein (TNFR:Fc) in patients with advanced heart failure
7. Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure; implications for clinical trials
8. Tumour necrosis factor-alpha in severe congestive cardiac failure
9. Tumor necrosis factor soluble receptors in patients with various degrees of congestive failure
10. The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia
11. Tumor necrosis factor gene and protein expression in adult feline myocardium after endotoxin administration
12. Soluble tumor necrosis factor binding proteins modulate the negative inotropic effects of TNF-a in vitro
13. Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure; relation to nitric oxide-dependent vasodilation in the forearm circulation
14. Drug-induced conditioning in congestive heart failure
15. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure
16. Circulating interleukin-6 in severe heart failure
17. Increased circulating cytokines in patients with myocarditis and cardiomyopathy
18. Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure
19. Adenosine decreases post-ischemic cardiac TNFa production; anti-inflammatory implications for preconditioning and transplantation
20. The clinical relevance of circulating tumor necrosis factor-a in acute decompensated chronic heart failure without cachexia
21. Role of cytokines in the mechanism of action of amlodipine; the PRAISE heart failure trial
22. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing
23. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing messenger RNA degradation
24. Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
25. Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression
26. Endotoxin and immune activation in chronic heart failure; a prospective cohort study
27. Plasma fas ligand, an inducer of apoptosis, and plasma soluble fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure
28. cAMP enhances inducible nitric oxide synthase mRNA stability in cardiac myocytes
29. Effect of amlodipine on morbidity and mortality in severe chronic heart failure
30. A prospective randomized controlled trial of prednisone for dilated cardiomyopathy
31. Beta-adrenergic blockade in developing heart failure; effects on myocardial inflammatory cytokines, nitric oxide, and remodeling
32. Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure
33. In vivo dynamics of murine tumor necrosis factor-a gene expression. Kinetics of dexamethasone-induced suppression
34. Thalidomide selectively inhibits tumor necrosis factor a production by stimulated human monocytes
35. Basic mechanisms in heart failure; the cytokine hypothesis
36. Randomized investigation of effects of pentoxifylline on left ventricular performance in idiopathic dilated cardiomyopathy
37. Inhibition of the inflammatory action of interleukin-1 and tumor necrosis factor (alpha) on neutrophil function by pentoxifylline
38. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension
39. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction; a report from the studies of left ventricular dysfunction (SOLVD)
40. Expression and functional significance of tumor necrosis factor receptors in human myocardium
41. Tumor necrosis factor-a and tumor necrosis factor receptors in the failing human heart
42. Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure
43. Long-term benefit of dobutamine in patients with congestive cardiomyopathy
44. Adenosine inhibitis lipopolysacchide-induced cardiac expression of tumor necrosis factor-a
45. Adenosine inhibits lipopolysaccharide-induced secretion of tumor necrosis factor-a in the failing human heart
46. Increased levels of serum neopterin and decreased production of neutrophil superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha
47. Inhibition of endogenous TNF formation by pentoxifylline